Drug Trial Radar · NCT07288398
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Jun 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Tenax Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.
Conditions
- Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103Drug
Oral levosimendan
PlaceboDrug
Matching placebo (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-Minute Walk Distance (6MWD)Time frame: 26 weeks
Locations
140 sites in 15 countries. Site status is shown where the registry gives one.
Tenax Investigational Site
Alexander City, Alabama
Tenax Investigational Site
Tucson, Arizona
Tenax Investigational Site
Sacramento, California
Tenax Investigational Site
San Francisco, California
Tenax Investigational Site
Stanford, California
Tenax Investigational Site
Torrance, California
Tenax Investigational Site
Athens, Georgia
Tenax Investigational Site
Atlanta, Georgia
Tenax Investigational Site
Chicago, Illinois
Tenax Investigational Site
Chicago, Illinois
Tenax Investigational Site
Mount Prospect, Illinois
Tenax Investigational Site
Peoria, Illinois
Tenax Investigational Site
Indianapolis, Indiana
Tenax Investigational Site
New Orleans, Louisiana
Tenax Investigational Site
West Monroe, Louisiana
Tenax Investigational Site
Boston, Massachusetts
Tenax Investigational Site
Ann Arbor, Michigan
Tenax Investigational Site
Ypsilanti, Michigan
Tenax Investigational Site
Minneapolis, Minnesota
Tenax Investigational Site
Rochester, Minnesota
Tenax Investigational Site
Kansas City, Missouri
Tenax Investigational Site
St Louis, Missouri
Tenax Investigational Site
Omaha, Nebraska
Tenax Investigational Site
Reno, Nevada
Tenax Investigational Site
New York, New York
Tenax Investigational Site
New York, New York
Tenax Investigational Site
Rochester, New York
Tenax Investigational Site
Durham, North Carolina
Tenax Investigational Site
Winston-Salem, North Carolina
Tenax Investigational Site
Cleveland, Ohio
Tenax Investigational Site
Columbus, Ohio
Tenax Investigational Site
Allentown, Pennsylvania
Tenax Investigational Site
Pittsburgh, Pennsylvania
Tenax Investigational Site
Wynnewood, Pennsylvania
Tenax Investigational Site
Charleston, South Carolina
Tenax Investigational Site
Nashville, Tennessee
Tenax Investigational Site
Austin, Texas
Tenax Investigational Site
Dallas, Texas
Tenax Investigational Site
El Paso, Texas
Tenax Investigational Site
Houston, Texas
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.